Semaglutide found to have shocking benefit for liver disease patients in new study
Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.
Semaglutide, which is traditionally a treatment for type 2 diabetes, was given to participants who had been diagnosed with a life-threatening form of liver disease called metabolic dysfunction associated steatohepatitis (MASH).
«This is a major step forward in the field,» said Arun Sanyal, M.D., director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, in a video from VCU. «It provides patients with additional choices when we think about treating fatty liver disease.»
JOE ROGAN GAVE UP DRINKING ALCOHOL FOR THIS ONE SIMPLE REASON
MASH is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), which was previously known as non-alcoholic fatty liver disease, according to WebMD.
Both MASH and MASLD are marked by excessive fat in the liver, which can be dangerous…